Neurocrine Biosciences, Inc.
NBIX
Rank in Stocks
#1555
Neurocrine Biosciences, Inc. is a pharmaceutical firm dedicated to the... Neurocrine Biosciences, Inc. is a pharmaceutical firm dedicated to the creation, advancement, and commercialization of medicines addressing a spectrum of neurological, endocrine, and psychiatric conditions. Its current therapeutic pipeline and marketed products target disorders such as tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, alongside numerous experimental compounds in various clinical stages. The company's primary commercial asset is INGREZZA, a VMAT2 inhibitor indicated for the management of tardive dyskinesia. Other available treatments include ONGENTYS, which serves as an auxiliary therapy for individuals with Parkinson's disease who are also receiving levodopa/DOPA decarboxylase inhibitors; ORILISSA, prescribed for the alleviation of moderate to severe pain linked with endometriosis in women; and ORIAHNN, an oral, non-surgical option for pre-menopausal women experiencing significant menstrual bleeding associated with uterine fibroids. Furthermore, Neurocrine is actively progressing a number of drug candidates through clinical development. These include NBI-921352 for treating pediatric patients and adult focal epilepsy; NBI-827104, designed to address rare pediatric epilepsy and essential tremor; NBI-1065845 for major depressive disorder; NBI-1065846 specifically for anhedonia within major depressive disorder; and NBI-118568 for the treatment of schizophrenia. The company also maintains strategic licensing and collaborative ventures with partners such as Heptares Therapeutics Limited, Takeda Pharmaceutical Company Limited, Idorsia Pharmaceuticals Ltd, Xenon Pharmaceuticals Inc., Voyager Therapeutics, Inc., BIAL Portela & Ca, S.A., Mitsubishi Tanabe Pharma Corporation, and AbbVie Inc. Neurocrine Biosciences, Inc. was founded in 1992 and operates from its headquarters in San Diego, California.
Share Price
$137.18
Last synced: 2026-10-19
Market Cap
$13.94B
Change (1 day)
1.08%
Change (1 year)
-2.94%
Country
US
Trade Neurocrine Biosciences, Inc. (NBIX)
Category
Healthcare
P/E ratio for Neurocrine Biosciences, Inc. (NBIX)
P/E ratio as of October 2026 TTM: 19.28
According to Neurocrine Biosciences, Inc. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 19.28. At the end of 2023 the company had a P/E ratio of 51.55.
P/E ratio history for Neurocrine Biosciences, Inc. from 2000 to 2026
P/E ratio at the end of each year
| Year | P/E Ratio | Change |
|---|---|---|
| 2026 (TTM) | 19.28 | -51.99% |
| 2024 | 40.15 | -22.11% |
| 2023 | 51.55 | -30.39% |
| 2022 | 74.06 | -17.64% |
| 2021 | 89.92 | 310.43% |
| 2020 | 21.91 | -91.77% |
| 2019 | 266.19 | -17.51% |
| 2018 | 322.70 | -773.76% |
| 2017 | -47.90 | 101.73% |
| 2016 | -23.74 | -55.83% |
| 2015 | -53.75 | 95.32% |
| 2014 | -27.52 | 103.30% |
| 2013 | -13.54 | -113.86% |
| 2012 | 97.68 | 682.49% |
| 2011 | 12.48 | -124.65% |
| 2010 | -50.65 | 2,328.12% |
| 2009 | -2.09 | 50.22% |
| 2008 | -1.39 | 66.81% |
| 2007 | -0.83 | -77.30% |
| 2006 | -3.67 | -96.47% |
| 2005 | -103.92 | 166.53% |
| 2004 | -38.99 | -33.19% |
| 2003 | -58.36 | 296.31% |
| 2002 | -14.73 | -59.30% |
| 2001 | -36.18 | 42.23% |
| 2000 | -25.44 | 0.00% |
P/E ratio for similar companies or competitors
| Company | P/E Ratio | P/E Ratio Difference | Country |
|---|---|---|---|
| 28.78 | 49.30% |
US
|
|
| -28.36 | -247.10% |
US
|
|
| -24.57 | -227.43% |
AU
|
|
| - | - |
CH
|
|
| 30.33 | 57.33% |
NL
|
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.